Skip to main content
    D

    DexCom Inc (DXCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $81.61
    -1.72 (-2.06%)

    Market Cap: $31.08B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    DexCom Inc (DXCM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect DexCom (DXCM) to earn $2.70 per share in the fiscal year ending Dec 31, 2026, on revenue of $5.23B. Of 29 analysts, 26 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $3.13.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 29 ratings average 1.97, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.

    RatingAnalystsShare
    Strong Buy413.8%
    Buy2275.9%
    Hold310.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    29

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 15.9% and revenue estimates rise 10.3%.

    Fiscal year ending Dec 31, 2026
    $2.70
    EPS consensus, revenue $5.23B
    Fiscal year ending Dec 31, 2027
    $3.13
    EPS consensus, revenue $5.77B
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.70$2.45 to $2.7825$5.23B$5.21B to $5.25B27
    Dec 31, 2027$3.13$2.76 to $3.4625$5.77B$5.71B to $5.90B27

    Quarterly Estimates

    The EPS consensus falls from $0.73 for the quarter ending Dec 31, 2026 to $0.64 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.73$0.66 to $0.8428$1.41B$1.33B to $1.48B28
    Mar 31, 2027$0.64$0.57 to $0.7417$1.31B$1.29B to $1.33B17

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Quarter ending Mar 31, 202725

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.1% from $2.67.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$2.70$2.67$2.66$2.66$2.67+1.3%
    Fiscal year ending Dec 31, 2027$3.13$3.13$3.12$3.13$3.13+0.2%
    Quarter ending Mar 31, 2027$0.64$0.64$0.64$0.64$0.64-1.0%

    Frequently Asked Questions About DXCM

    What is the DXCM stock forecast?

    Consensus analyst estimates put DexCom's EPS at $2.70 for the fiscal year ending Dec 31, 2026, on revenue of $5.23B. The consensus rating from 29 analysts is Buy.

    How do analysts rate DXCM stock?

    Of 29 analysts covering DexCom, 4 rate it Strong Buy, 22 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from DXCM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.70, with estimates from $2.45 to $2.78 from 25 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.13, with estimates from $2.76 to $3.46 from 25 analysts.

    What revenue do analysts expect from DexCom next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $5.23B, with estimates from $5.21B to $5.25B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.77B, with estimates from $5.71B to $5.90B.

    How many analysts cover DXCM?

    29 analysts rate DexCom stock, and 25 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.